Author Index to Volumes 21, 22, and 23

Abi-Hanna D, 21:233
Aguiar W, 21:155
Allen CI, 22:51
Alper CA, 21:23, 133
Amos B, 21:1, 79, 23:1
Ando A, 21:239
Argon Y, 22:81
Ashman RF, 21:155
Awdeh ZL, 21:23, 133

Baker L, 23:289
Balakrishnan K, 22:227
Balbas O, 23:45
Bangham CRM, 21:125
Barry TS, 22:185
Batchelor JR, 22:31
Beresford N, 22:247
Bernard A, 23:163
Blumenthal M, 21:23
Bodmer JG, 23:37
Bonneville M, 23:207
Bontrop RE, 23:271
Boumsell L, 23:163
Bowerman P, 22:135
Bradley BA, 22:135
Brautbar C, 21:15
Buckley R, 21:233
Bugawan TL, 21:249
Burckart G, 21:143
Burley MW, 22:31
Bushell A, 21:125, 23:191
Buurman WA, 22:97

Carbonara A, 21:193
Carrington MN, 22:275
Cavalli-Sforza LL, 22:111
Charlesworth J, 21:233
Charoenwong P, 23:27
Charron DJ, 23:207
Chatila M, 21:89
Chertkoff LP, 23:241
Chien MM, 21:155
Choo SY, 21:209
Christiansen FT, 23:27
Claas FHJ, 22:163
Clark EA, 21:33
Cobain TJ, 21:165
Cooke H, 22:135
Costello W, 21:23
Cotner T, 22:263

Dasgupta JD, 21:133
Davey NJ, 22:31
Dawkins RL, 21:165, 23:27
Dawson JR, 21:1, 79, 22:81
de Lange G, 22:163
Denegri JF, 22:39
Dubey DP, 22:151
Dubowitz V, 22:31
Dunlevy JR, 22:81
Duquesnoy RJ, 21:143

Eckels DD, 21:173, 279
Eisera N, 22:73
Emara M, 23:223
Engardt SE, 21:155
Erlich HA, 22:61, 249

Fabian I, 21:81
Fabio G, 22:73
Fainboim L, 23:241
Fajardo MA, 22:151
Falk JA, 23:5
Ferrara GB, 21:265
Ferrone S, 21:193, 23:255
Festenstein H, 23:179
Fielder AHL, 22:31
Finn OJ, 22:185, 23:223
Flaherty L, 21:3
Fleischnick E, 21:23
Friedmann A, 21:15
Frumento G, 21:265

Gabbay KH, 22:51
Gaiser CN, 22:111
Garcia E, 23:45
Gatti RA, 22:145
Gaudernack G, 22:235
Gerald PS, 21:23
Giphart M, 22:247
Giphart MJ, 23:271
Given SR, 22:151
Glass DN, 21:89, 22:227
Golding J, 21:233
Goeken NE, 21:99
Gorski J, 22:171
Gratama JW, 22:163
Gregersen PK, 22:179
Gyodi E, 22:19

Hammerling U, 21:221, 265
Hancock RJT, 22:135
Hansen JA, 21:63, 209, 289, 22:51, 263, 23:289
Heinen HD, 23:45
Herrera M, 23:241
Hirayama K, 22:9
Holbeck SL, 21:183
Hole N, 22:247
Honda Y, 23:23
Horn GT, 21:249
Huber C, 22:19
Huet S, 23:163

Inoko H, 21:239

Jager MJ, 22:163
Jorgensen L, 21:49
Juji T, 23:23

Kaiser G, 22:19
Kamikawaji N, 22:9
Kamoun M, 23:289
Kao KJ, 21:115
Kassai M, 22:19
Katovich Hurley C, 22:179
Kay PH, 21:165, 23:27

Kenny T, 22:247
Knowles RW, 22:123
Koning F, 21:49
Kosinski S, 21:221
Kotlan B, 22:19
Koyama M, 22:145

Lang B, 23:59
Larson MG, 22:227
Laundy GJ, 22:135
Lavie P, 21:15
Layrisse Z, 23:45
Lazzarin A, 22:73
Ledbetter JA, 23:281
Letarte M, 23:5
Levinson JE, 22:227
Lindsay J, 23:37
LoGalbo PR, 23:59
Long CM, 21:249, 22:61
Long EO, 21:173
Longo A, 21:265
Lord DH, 22:31
Lundin KE, 22:235
Luyrink L, 21:89

MacDonald MJ, 22:51
Maeda M, 21:239
Mahe Y, 23:163
Mahoney RJ, 22:151
Makowka L, 21:143
Manos MM, 21:249
Martin A, 22:135
Masewicz SA, 22:263
Matsuki K, 23:23
Matsushita S, 22:1, 9
Mazzoleni O, 21:265
McCluskey P, 21:233
McEleney J, 21:89
McKinnon KP, 22:81
McMain A, 22:247
McQueen CF, 21:115
Meier-Ewert K, 22:221
Merdrignac G, 23:207
Miceli MC, 22:185, 23:223
Mickelson EM, 21:63, 289, 22:51, 263, 23:289
Monos DS, 23:289
Moreau JF, 23:207
Morimoto C, 22:1
Moroni M, 22:73
Morris A, 22:247
Morris PJ, 21:125, 23:191
Mota AH, 23:241
Mueller-Eckhardt G, 22:221
Murase N, 21:143

Nagata Y, 21:239
Nakhooda AF, 23:5
Navarette C, 23:179
Neil D, 23:281
Nepom GT, 21:63, 183, 289
Nisperos B, 21:63

Oksenberg JR, 22:111
Okumura M, 22:9
Ono R, 21:193
Orr HT, 21:209

Padanyi A, 22:19
Palavecino E, 23:241
Park MS, 21:193
Park S, 22:151
Peled R, 21:15
Pena AS, 23:271
Pera S, 22:135
Perosa F, 23:255
Petranyi GG, 22:19
Petri I, 22:19
Peyrat MA, 23:207
Pilarski LM, 23:281
Pincus SH, 22:199
Pistillo MP, 21:221, 265
Pulleyblank BMS, 23:5
Pussel B, 21:233

Qvigstad E, 22:235

Relias V, 21:133
Richiardi P, 21:193
Riley WJ, 21:115
Rinke de Wit T, 22:247
Risk J, 22:247
Robb SA, 22:31
Robbins FM, 22:171
Roberts I, 22:135
Roep BO, 23:271
Rose LM, 21:33
Rose M, 23:179
Rowe JR, 21:49, 22:51

Sackett GP, 21:33
Sakaguchi K, 21:193
Salser W, 22:145
Sanchez B, 23:59
Sanfilippo F, 23:223
Satz ML, 23:241
Saunders CE, 22:31
Sasazuki T, 22:1, 9
Scharf SJ, 22:61
Schlossman SF, 22:1
Schneider PM, 21:23
Schot JDL, 22:163
Schroeijers WEM, 22:171
Scornik JC, 21:115
Scorza Smeraldi R, 22:73
Sekaly RP, 21:173
Sell TW, 21:173
Serra HM, 23:281
Seyfried CE, 21:289
Shaked R, 22:145
Sheehy MJ, 21:49, 22:51
Silver J, 22:145, 179
Smythe J, 22:135
Sollid LM, 22:235
Soulillou JP, 23:207
Spies T, 21:89
Staggs TS, 21:99
Starzl TE, 21:143
Steiner N, 22:179
Steinman L, 21:15, 22:111
Stern PL, 22:247
St John T, 21:209
Stoikow Z, 23:45
Strachan T, 22:247
Strohmaier P, 22:221
Strominger JL, 21:89
Sutton VR, 22:123
Szabo T, 22:19

Takacs K, 22:19
Tanigaki N, 21:265, 22:171
Terao K, 21:33
Terasaki PI, 21:193
Termijtelen A, 22:171
Thorsby E, 22:235
Tilanus MGJ, 22:171
Tokunaga K, 23:27
Tonai R, 21:193
Tosi R, 22:171
Troppmair J, 22:19
Trowsdale J, 23:37
Truedsson L, 21:23
Tsuji K, 21:239
Tsujisaki M, 21:193
Tursz T, 23:163

Uberti Foppa C, 22:73
Uryu N, 21:239

van Eggermond MCJA, 23:271
van Kerckhove C, 22:227
van Leeuwen A, 22:247
van Rood JJ, 21:79, 22:163, 171, 23:1, 271
van Thiel DH, 21:143
Venkataramanan R, 21:143

Wakasugi H, 23:163

Wakefield D, 21:233
Wang CP, 21:143
Ward FE, 22:275
Watanabe H, 22:9
Weber WEJ, 22:97
Wei S, 22:145
Whitehead AS, 21:23
Williams Z, 21:81
Williamson J, 23:27
Wilner A, 21:15
Wilson L, 22:247
Winchester R, 23:59
Wood KJ, 21:125, 23:191

Yacoub M, 23:179
Yang SY, 21:221
Yokoyama WM, 21:155
Young JAT, 23:37
Yunis EJ, 21:23, 133, 22:51, 151

Zanussi C, 22:73
Zeevi A, 21:143
Zhang WJ, 21:165
Ziff BL, 22:179
Zmijewski M, 23:289

Subject Index to Volumes 21, 22, and 23

Abstracts, ASHI 14th Annual Meeting, San Francisco, CA, 23:75
Activated lymphocytes, sensitivity to cyclosporine and its metabolites, 21:143
Activated T cells, expression of HLA-DPw1 class II molecules, 21:279
Adenosine and deoxyadenosine, effect on bone marrow cells, 21:81
Allograft-derived T-cell lines (human), donor class I- and class II-directed cytotoxicity, 22:185
Alloimmune reactions, induced by leukocyte and platelet transfusions, a comparative study, 22:19
Alloreactive T-cell clone, recognition of a shared determinant in HLA-Dw14 and HLA-DR3, 23:59
Anterior uveitis, association with complement C4B2 allotype, 21:233
Anti-HLA-DR, DP monoclonal antibody, characterization of an antiidiotypic monoclonal antibody to, 23:255
Anti-μ chain, stimulation of B-cell membrane depolarization and cell volume changes, 21:155
Anti-mycoplasma drugs, selection of an MHC class II-negative variant melanoma cell line by, 22:275
Antigen presentation, influenza hemagglutinin peptide by HLA-DR1 transfected human fibroblasts, 21:173
ASHI, Abstracts of 14th Annual Meeting, 23:75
ASHI, an editorial, 21:79

B-cell growth factor, stimulation of B-cell membrane depolarization, 21:155
B-cell membrane depolarization, stimulation by either anti-μ chain or B-cell growth factor, 21:155
B-cell volume changes, stimulation by anti-μ chain, 21:155
Bone marrow cells, effect of deoxycoformycin and adenosine, 21:81

C4 allotyping, plasma or serum, 21:165
C4 complement allotypes, in juvenile dermatomyositis, 22:31
Carbonylcyanide m-chlorophenylhydrazone (CCCP), inhibition of cell-mediated cytotoxicity, 22:81
CD2 and CD3 signals, T-cell activation, 23:163
Celiac disease, an associated HLA-DQα allele, 23:271
Cell-mediated cytotoxicity, inhibition of effector cell granule reorientation by a protonophore, 22:81
Ceppellini, Ruggero, in memoriam, 23:1
Complement C4 allotyping, plasma or serum, 21:165
Complement C4 DNA variants, relationship to MHC alleles and extended haplotypes, 21:23
Complement C4B2 allotype, association with anterior uveitis, 21:233
Complotypes, *see* Complement C4 DNA variants
Computer program, interactive, analysis of HLA class II RFLPs, 21:125
Cryptomeria japonica pollen antigen, blocked suppression of the immune response by monoclonal antibody 4B4, 22:1
Cyclosporine and its metabolites, sensitivity of human activated lymphocytes to, 21:143

Deoxycoformycin, effect on bone marrow cells, 21:81
Dermatomyositis, juvenile, C4 complement allotypes in, 22:31
Diabetes mellitus, insulin-dependent analysis of DR and DQ gene products of DR4 haplotype in patients, 23:289

sequence analysis of HLA class II genes, 21:249
T-cell-defined DR4 subtypes as markers, 22:51
Differentiation antigens, thymocyte, serologic identification, 22:151
DNA polymorphism, human Thy-1 gene, 22:145
DNA polymorphisms, human Ig heavy-chain variable-region genes, 22:199
Double determinant immunoassay, an application, 21:193
DPα chain-β chain interaction, influence on an epitope recognized by a DPα chain-specific monoclonal antibody, 23:37
DR/DQ unique associations, in Warao Amerindians, 23:45
DR2/DQw1 haplotype, no male segregation distortion in Japanese narcoleptic patients, 23:23
Dw14 and DR3 haplotypes, shared functional epitope recognized by an alloreactive T-cell clone, 23:59

Editorials
major histocompatibility complex evolution and function, 21:1
welcome to ASHI, 21:79
Epitope recognition, by monoclonal antibody DP11.1, influence of interaction between the DPα chain and its polymorphic DPβ chain partner, 23:37
Extended haplotypes
C4 complement allotypes in juvenile dermatomyositis, 22:31
human complement C4 DNA variants and relationship to MHC alleles, 21:23
two variants of DR-3 bearing extended haplotypes, 21:133

Gene families, human Ig heavy chain variable regions, 22:199
Gene sequence registry, DR and DQβ cDNA sequences associated with a DR2 haplotype, 22:179

Heart allografts, persistence of donor-specific class II antigens in, 23:179
Hepatitis B surface antigen, control of nonresponsiveness to by an immune suppression gene on HLA-Bw54-DR4-DRw53, 22:9
HLA and altered sex ratios, juvenile rheumatoid arthritis sibships, 22:227
HLA-associated susceptibility to AIDS, HLA-B35 a major risk factor in Italian drug addicts, 22:73
HLA-B7 crossreacting group, monoclonal antibodies and antiidiotypic monoclonal antibodies, 21:193
HLA B17, BfS, C4A6, B1, DR7 and DQw9 chromosomal segment, coexistence in different ethnic groups, 23:27
HLA-B27d (HLA-B*2703), molecular analysis of a variant alloantigen, 21:209
HLA-B35, a major risk factor for AIDS in Italian intravenous drug addicts, 22:73
HLA-B35 gene, DNA polymorphism associated with different HLA-C locus alleles, 23:241
HLA-Bw54-DR4-DRw53 haplotype, immune suppression gene on, control of nonresponsiveness to hepatitis B surface antigen, 22:9
HLA class II antigens, persistence of donor-specific in allografted human heart, 23:179
HLA class II genes, sequence analysis in insulin-dependent diabetes, 21:249
HLA class II molecules, expression on T-cell clones, 23:207
HLA class II RFLPs, analysis by an interactive computer program, 21:125
HLA-C locus alleles, association with DNA polymorphism of the HLA-B35 gene, 23:241
HLA-DP, typing, analysis of DNA RFLP in HLA-DPβ subregion, 21:239
HLA-DPβ subregion, analysis of DNA RFLP, 21:239
HLA-DQα allele, association with celiac disease, 23:271
HLA-DQβ3.1 genes, molecular analysis, 21:183
HLA-DQw3, allelic variants, molecular analysis of HLA-DQβ3.1 genes, 21:183
HLA-DQw3 variants, defined by alloreactive T-cell clones, 21:63
HLA-DQw3.2-associated epitope, involving residue 57 on the DQβ chain, 22:235
HLA DR and DQ gene products of the DR4 haplotype, analysis in patients with insulin-dependent diabetes mellitus, 23:289
HLA-DRβ4 chain, defective expression associated with RFLP in the HLA-DRB1 gene, 22:123

HLA-DR compatible renal allografts, mismatches identified by genomic analysis, 23:191
HLA-DR molecules, epitope analysis of those expressed on alloreactive T-cell clones, 23:207
HLA-DR, T-cell recognition epitope shared by diverse specificities, 21:289
HLA-DR1 and HLA-DRw9, shared supertypic determinant crossreactive with HLA-DR2, 21:221
HLA-DR1 transfected human fibroblasts, antigen presentation by in the presence of limited allostimulation, 21:173
HLA-DR2 haplotype
association with narcolepsy in Israeli Jews, 21:15
DR- and DQβ cDNA sequences associated with, 22:179
narcolepsy-specific alterations, a cellular approach, 22:221
HLA-DR3-bearing extended haplotypes, two variants, 21:133
HLA-DR4 and HLA-DR1, a shared T-cell recognition epitope, 21:289
HLA-DR4 haplotype, analysis of DR and DQ gene products in patients with insulin-dependent diabetes mellitus, 23:289
HLA-DR4 subtypes, T-cell defined as markers for insulin-dependent diabetes mellitus, 22:51
HLA-DR4/DRw6 shared amino acid sequences, 22:61
HLA-DR5 (DRw11), production of human monoclonal antibody to, 22:135
HLA-DRB1 gene, RFLP associated with defective expression of the DRβ4 chain, 22:123
HLA-DRβ and HLA-DQβ loci, sequence analysis in Pemphigus vulgaris patients, 22:61
HLA-DRβIII chain, functional polymorphism, 21:49
HLA-DRw52-associated epitopes, recognition of, 22:171
HLA-DRw52-associated RFLPs, 21:89
HLA-DRw52, DR3, and DQw2 specificities, two variants that distinguish different DR3-bearing extended haplotypes, 21:133
HLA-DRw52 haplotypes, correlations between polymorphisms at the DNA and protein level, 22:171
HLA-DRw52 subtypes, DNA and protein polymorphisms, correlation by a number of techniques, 22:171
HLA-DRw52 supertype, splitting by RFLP analysis, 21:89
HLA-DRw52 variants, defined by T-cell clones, 22:263
HLA in plasma, association of concentration with HLA phenotype, 21:115
HLA phenotype, association with HLA concentration in plasma or platelets, 21:115
HMA-1 and HMA-2 human monocyte antigens, 22:163
Human monoclonal anti-HLA antibodies, a review, 21:265
Human monoclonal antibody
production to HLA-DR5 (DRw11) by mouse/human heterohybridomas, 22:135
recognition of a supertypic HLA class II determinant, 21:221

IL-1
human T-cell activation, 21:99
T-cell activation, 23:163
Immune suppression gene on HLA-Bw54-DR4-DRw53, control of nonresponsiveness to hepatitis B surface antigen, 22:9
Immunoglobulin (Ig) heavy-chain variable regions (human), gene families, 22:199
Immunoglobulin secretion, pokeweed mitogen induced, inhibition by IgG MoAbs to MHC class I and class II molecules, 23:5
Inflammatory eye disease, *see* Anterior uveitis
Interleukin 1, *see* IL-1
Israeli Jews and narcolepsy, *see* Narcolepsy

Juvenile dermatomyositis, *see* Dermatomyositis, juvenile

Leukocyte transfusion, induction of alloimmune reactions, 22:19
Lymphocyte subsets, development in pigtailed macaques, 21:33

Major histocompatibility complex evolution and function, an editorial, 21:1
Major histocompatibility complex polymorphism, nonimmune theory for selection, 21:3

Melanoma, loss of MHC class II expression on a cell line following treatment with anti-mycoplasma drugs, 22:275
Membrane-bound IL-1, *see* IL-1
Memory cells, expression of the VG01 antigen, 22:39
MHC class I expression, TCA-positive teratocarcinoma stem cells, 22:247
MHC class II expression, loss of following treatment of a melanoma cell line with anti-mycoplasma drugs, 22:275
Monoclonal antibody
  4B4 blocks suppression of the immune response, 22:1
  antiidiotypic, recognition of idiotopes shared by monoclonal antibodies detecting an HLA-B7 crossreacting epitope, 21:193
  determinant shared by HLA-B7, B27, Bw42, Bw55, Bw56, Bw67, and Bw73, 21:193
  DPα chain-specific, DP11.1, epitope recognition, 23:37
  human anti-HLA, 21:265
  human, defining a supertypic HLA class II determinant, 21:221
  inhibition of PWM-induced Ig secretion by antibodies to MHC class I and class II molecules, 23:5
  syngeneic to a murine anti-HLA-DR, DP monoclonal antibody, 23:255
Monocyte antigens (human), genetics of two markers, 22:163
Mouse/human heterohybridomas, production of a human monoclonal antibody to HLA-DR5 (DRw11), 22:135
Multiple sclerosis (MS)
  frequency of polymorphic markers for T-cell receptor α and β genes in, 22:111
  myelin basic protein-specific T-cell clones, CD4+ cytolytic clones, 22:97
Myasthenia gravis (MG), frequency of polymorphic markers for T-cell receptor α and β genes in, 22:111
Myelin basic protein-specific T-cell clones, CD4+ cytolytic clones from MS patients, 22:97

Narcolepsy
  association with HLA-DR2 haplotype in Israeli Jews, 21:15
  detection of alterations in DR2 haplotypes, a cellular approach, 22:221
  no male segregation distortion of DR2 haplotypes in Japanese, 23:23
Natural killer (NK) cells, expression of the VG01 antigen, 22:39
Nonimmune theory of selection, MHC polymorphism 21:3

Obituary, Ruggero Ceppellini, 23:1

Pemphigus vulgaris, sequence analysis of HLA-DRβ and HLA-DQβ loci from patients, 22:61
Pigtailed macaques, development of lymphocyte subsets, 21:33
Platelet HLA, relationship with HLA phenotype, 21:115
Platelet transfusions, alloimmune reactions, 22:19
Pokeweed mitogen-induced Ig secretion, inhibition by monoclonal antibodies to class I and class II molecules, 23:5

Renal allografts
  identification of class II mismatches by genomic analysis in serologically DR-compatible, 23:191
  in vitro induction of suppressor T cells, 23:223
Rheumatoid arthritis, juvenile, HLA and altered sex ratios, 22:227

Secreted IL-1, *see* IL-1
Segregation distortion of DR2 haplotypes, in Japanese narcoleptic patients, 23:23
Stem cells, *see* Bone marrow cells
Supertypic HLA class II determinant, shared by HLA-DR1 and DRw9, crossreactive with DR2, 21:221
Suppressor T-cells, induction by in vitro culture with an autologous renal allograft-derived T cell line, 23:223
Supratype HLA B17, BfS, C4A6, B1, DR7, coexistence in different ethnic groups, 23:27

T cell, loss of 2H4+ population after fixation, an artifact, 23:281
T-cell activation
  comparison of signals delivered through CD3 and CD2, 23:163
  IL-1 requirement, 21:99
T-cell clones
  alloreactive, define HLA-DQw3 variants, 21:63
  alloreactive, epitope analysis of HLA-DR molecules on, 23:207

definition of HLA-DRw52 variants, 22:263
functional polymorphism of HLA-DRβII chain, 21:49
HLA-DPw1-associated determinants, 21:279
myelin basic protein-specific, CD4+ cytolytic clones, isolation from MS patients, 22:97
recognition of an HLA-DQw3.2-associated epitope on the DQβ chain, 22:235
recognition of a shared determinant in HLA-Dw14 and HLA-DR3, 23:59
T-cell expression of HLA-DPw1 class II molecules, 21:279
T-cell lines, human allograft-derived, donor class I- and class II-directed cytotoxicity, 22:185
T-cell population dynamics, human allograft-derived T-cell lines, 22:185
T-cell receptor (human) α and β genes, frequencies of polymorphic markers in families and patients with MS and MG, 22:111
T-cell recognition epitope, specific nucleotide sequence shared by diverse HLA-DR specificities, 21:289
T-cell suppression, immune response to cryptomeria japonica pollen antigen, inhibition with monoclonal antibody 4B4, 22:1
T-cell-defined DR4 subtypes, markers for insulin-dependent diabetes mellitus, 22:51
TCA system, expression on teratocarcinoma stem cells, 22:247
Teratocarcinoma stem cells, MHC class I expression, 22:247
Thy-1 gene (human), DNA polymorphism, 22:145
Thymocyte differentiation antigens, serologic identification, 22:151
Transfusion-induced alloimmune activation, 22:19
Transspecies hypothesis, MHC polymorphism, 21:3

Variant alloantigens, molecular analysis of HLA-B27d (HLA-B*2703), 21:209
VG01 antigen, expression on NK and memory cells, 22:39

Warao Amerindians, unique HLA DR/DQ associations, 23:45